Despite improvement of locoregional control, the long-term survival of HNSCC patients remains disappointing. The current five year survival rate for this type of cancer is less than 50%, and this percentage has only increased slightly for the last three decades. Increasingly more treatment protocols are applied. Treatment consists of surgery, radiotherapy or a combination of these modalities. For more advanced stages chemoradiation can be applied, the concomitant application of systemic cisplatin combined with locoregional radiotherapy. Also targeted therapies have been introduced, mostly focusing on the epidermal growth factor receptor (EGFR) with the antibody cetuximab. There is a major challenge to personalize current therapies and to develop novel targeted treatments, which is the aim of this program.